Viz.ai Partners with 3 Pharma Companies, Expands to 60,000 Providers
Viz.ai, a leader in AI-powered disease detection and care coordination, has announced major achievements in its mission to revolutionize healthcare delivery. In 2024, the company formed partnerships with three of the largest global pharmaceutical companies, bringing its total number of collaborations with top life science firms to 10. Additionally, Viz.ai expanded its services to 1,700 hospitals, increasing its user base by over 30%, now reaching 60,000 healthcare providers across the U.S. This rapid growth, driven by new product innovations and real-world evidence, underscores Viz.ai’s commitment to broadening access to life-saving treatments.
Viz.ai, a pioneer in AI-powered disease detection and intelligent care coordination, has had a highly successful year, surpassing expectations and solidifying its position as a trusted leader in healthcare technology. Dr. Chris Mansi, CEO and co-founder of Viz.ai, remarked, “This year has surpassed our expectations as Viz.ai’s footprint in healthcare continued to grow, with the majority of the 50 largest healthcare systems in the U.S. adopting our platform.
This reaffirms our position as the leading, trusted AI-powered platform and highlights our commitment to providing tools that empower healthcare providers, streamline workflows, and improve patient outcomes. As we move forward, we aim to accelerate patient care by leveraging AI-driven insights and care coordination in 2025.”
In 2024, Viz.ai introduced several groundbreaking products and capabilities to its Viz.ai One™ enterprise platform. Now equipped with over 48 clinical AI modules, the platform includes new innovations such as the Viz ICH Plus™ algorithm, which provides automated volumetric assessment, and advanced 3D CT angiography functionality. Additionally, Viz.ai launched Viz Connect® for cryptogenic stroke and Viz ACS for acute coronary syndrome, further enhancing its offerings in cardiovascular and neurovascular care pathways. These new features ensure that Viz.ai’s platform supports both acute and non-acute treatment scenarios, emphasizing the company’s dedication to transforming healthcare with cutting-edge AI solutions.
In addition to expanding its product portfolio, Viz.ai has continued to showcase its impact through clinical studies and publications. In 2024 alone, the company initiated 24 new clinical studies, and it now boasts over 100 clinical publications and abstracts. These studies have consistently demonstrated the positive influence of Viz.ai’s AI-powered care coordination on patient outcomes and healthcare efficiency.
Notably, three studies presented at the American College of Cardiology Scientific Sessions 2024 highlighted the benefits of Viz.ai’s hypertrophic cardiomyopathy module in disease detection and patient triage. Furthermore, a study on pulmonary embolism (PE) showed that the Viz PE solution reduced in-hospital mortality risk by 74% by significantly improving time to assessment and anticoagulation. At the International Stroke Conference (ISC) 2024, six studies demonstrated Viz.ai’s positive impact on clinical practice for conditions such as acute ischemic stroke, cryptogenic stroke, unruptured cerebral aneurysms, and brain hemorrhages.
Viz.ai’s growth has been driven by strategic partnerships with prominent healthcare organizations. During the Radiological Society of North America (RSNA) meeting, Viz.ai announced a collaboration with Microsoft to deliver a comprehensive platform that integrates over 48 diagnostic imaging AI models into clinical workflows. The partnership aims to assist radiologists in creating more accurate reports efficiently while streamlining communication with treating physicians and enhancing care team collaboration. Additionally, company formed partnerships with Cleerly at the American College of Cardiology meeting and with Addario Lung Cancer Medical Institute at the American Society of Clinical Oncology meeting, further extending its reach across cardiology, oncology, and neurology.
In recognition of its innovation and contributions to healthcare, company received several prestigious accolades in 2024. The company was named to Fast Company’s 50 Most Innovative Companies list and received the Prix Galien Award for Best Digital Health Solution in Pharma. Additionally, company won its second Edison Award for its Viz Pulmonary Embolism solution. Dr. Chris Mansi was also named one of the 100 most influential people in AI by TIME Magazine. These honors reflect company’s success in expanding patient access to life-saving treatments through its advanced AI technologies.
It continues to make a significant impact in healthcare, using AI to improve diagnosis speed and care coordination across over 1,700 hospitals and health systems in the U.S. and Europe. The company’s AI-powered Viz.ai One™ platform helps identify more patients with suspected diseases, informs critical decisions at the point of care, and optimizes care pathways, ultimately improving outcomes. With strong real-world clinical evidence backing its solutions, this continues to provide value to patients, healthcare providers, and the broader healthcare ecosystem, including pharmaceutical and medical device companies.
Please find the related post
